Hepatocellular carcinoma treated with MRI-gated SBRT. From Mittauer et al. Cureus 2018;10:e2422. Used with permission.
Treating Tumors that Move: The Promise and Practice of Real-time MR Image Guidance During Radiation Beam Delivery
September 20, 2018 - 2:00 PM Eastern
Respiratory tumor motion often complicates the delivery of precision radiation treatment. Over the past two decades, radiotherapy researchers and clinicians have pursued several approaches to motion management, however, the approaches lacked continuous, high-quality soft tissue visualization linked to an automated beam-gating technology that would see when a tumor moved out of margin range and halt the delivery of radiation until it returned to a prescribed area (PTV).
With the introduction of magnetic resonance image (MRI) guidance and real-time image guidance during beam delivery, the ability to lessen or eliminate radiation dose to surrounding tissues and organs is achievable. Several studies have demonstrated (1) the ability to reduce to a minimum the margin expansion necessary to account for motion error while reducing doses to nearby organs at risk and (2) the ability to obtain duty cycles equal to or greater than those common to conventional gating.
In this webinar, two speakers will share their clinical experience with this MRI-Guided RT technology.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.